文献速递肝病消化道肿瘤与早癌

连续风险评分可预测肝细胞癌患者的等待名单及移植后结局,尽管豁免政策发生变化

Continuous Risk Score Predicts Waitlist and Post-transplant Outcomes in Hepatocellular Carcinoma Despite Exception Changes.
PubMed 文献 · Clin Gastroenterol Hepatol · 2024-06-20

本研究利用UNOS数据库(2012-2021)构建并验证竞争风险模型,评估HALT-HCC评分对23,858例肝细胞癌候选者等待名单脱落和移植后结局的区分能力。HALT-HCC评分越高,脱落发生率越高、移植后预测5年总生存率越低;其预测脱落AUC在6个月为0.68、1年为0.66,校准良好。作者主张将HALT-HCC等连续评分系统整合进肝脏分配决策。

要点

  • HALT-HCC评分越高,等待名单脱落发生率越高。
  • HALT-HCC评分越高,移植后预测5年总生存率越低。
  • HALT-HCC预测脱落AUC为6个月0.68、1年0.66,校准良好。

核心结论

  • 连续肿瘤学风险评分HALT-HCC可预测肝细胞癌患者的等待名单脱落和移植后结局,且不受政策变化影响。
  • 作者主张将HALT-HCC等连续评分系统整合进肝脏分配决策,以平衡紧迫性、器官效用和生存获益。

研究设计与样本

  • 利用UNOS数据库(2012-2021)构建并验证竞争风险模型,涵盖多次政策变更期间。
  • 研究纳入23,858例候选者,其中14,646例(59.9%)接受肝移植,5,196例(21.8%)从等待名单脱落。
  • 主要结局为评估等待名单脱落和肝移植结局的区分能力,重点比较HALT-HCC评分与其他肝细胞癌风险评分。

主要发现

  • HALT-HCC评分越高,等待名单脱落发生率越高,且移植后预测5年总生存率越低。
  • HALT-HCC预测等待名单脱落的AUC在列表后6个月为0.68、1年为0.66,校准R²在6个月为0.95、1年为0.88。
  • HALT-HCC的准确性在各政策时期和局部区域治疗应用下保持稳定。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Continuous risk-stratification of candidates and urgency-based prioritization have been utilized for liver transplantation (LT) in patients with non-hepatocellular carcinoma (HCC) in the United States. Instead, for patients with HCC, a dichotomous criterion with exception points is still used. This study evaluated the utility of the hazard associated with LT for HCC (HALT-HCC), an oncological continuous risk score, to stratify waitlist dropout and post-LT outcomes. METHODS: A competing risk model was developed and validated using the UNOS database (2012-2021) through multiple policy changes. The primary outcome was to assess the discrimination ability of waitlist dropouts and LT outcomes. The study focused on the HALT-HCC score, compared with other HCC risk scores. RESULTS: Among 23,858 candidates, 14,646 (59.9%) underwent LT and 5196 (21.8%) dropped out of the waitlist. Higher HALT-HCC scores correlated with increased dropout incidence and lower predicted 5-year overall survival after LT. HALT-HCC demonstrated the highest area under the curve (AUC) values for predicting dropout at various intervals post-listing (0.68 at 6 months, 0.66 at 1 year), with excellent calibration (R2 = 0.95 at 6 months, 0.88 at 1 year). Its accuracy remained stable across policy periods and locoregional therapy applications. CONCLUSIONS: This study highlights the predictive capability of the continuous oncological risk score to forecast waitlist dropout and post-LT outcomes in patients with HCC, independent of policy changes. The study advocates integrating continuous scoring systems like HALT-HCC in liver allocation decisions, balancing urgency, organ utility, and survival benefit.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Akabane M, McVey JC, Firl DJ, et al. Continuous Risk Score Predicts Waitlist and Post-transplant Outcomes in Hepatocellular Carcinoma Despite Exception Changes. Clin Gastroenterol Hepatol. 2024. PMID: 38908731. doi:10.1016/j.cgh.2024.05.046

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。